BRIEF-FDA grants Merrimack fast track designation for Seribantumab (mm-121) in non-small cell lung cancer

* FDA Grants Merrimack fast track designation for Seribantumab (Mm-121) in non-small cell lung cancer
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.